VGX™ Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases, including HIV, as well as cancer and inflammatory diseases. The Company's clinical development programs include PENNVAX™-B, a DNA vaccine for the prevention of HIV in Phase I clinical trials; VGX-1027, a small molecule drug for inflammatory diseases in Phase I clinical trials; VGX-3100, a DNA therapetic vaccine for cervical cancer in Phase I clinical trials; and CELLECTRA^® delivery device in Phase I clinical trials.

In addition, VGX has filed INDs for VGX-3200 and VGX-3400 for cancer cachexia and avian influenza, respectively.

The lead therapeutic programs in infectious diseases and oncology are well complemented by a strong research pipeline of next-generation DNA vaccines. VGX’s proprietary content, coupled with a patented DNA delivery system (CELLECTRA^® electroporation), and acess to state-of-the-art cGMP plasmid Manufacturing capabilities form the Company’s DNA Vaccines and Therapies Platform, which gives VGX a unique position relative to its peers with DNA vaccines and therapeutics programs.